Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Jiangsu Nhwa Pharmaceutical Co., LTD
  6. News
  7. Summary
    002262   CNE100000CG8

JIANGSU NHWA PHARMACEUTICAL CO., LTD

(002262)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Jiangsu Nhwa Pharma Signs Nearly $18 Million Deal to License Lundbeck's Schizophrenia Drug

11/29/2021 | 01:33am EST


ę MT Newswires 2021
All news about JIANGSU NHWA PHARMACEUTICAL CO., LTD
2021Jiangsu Nhwa Pharma Signs Nearly $18 Million Deal to License Lundbeck's Schizophrenia D..
MT
2021Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended..
CI
2021Jiangsu Nhwa Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended J..
CI
2021Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmac..
CI
2021TREVENA : Enrolls First Patient in Late-Stage Study of Olinvyk Injection in China
MT
2021Trevena, Inc. Announces First Patient Enrolled in OLINVYK« Phase 3 Trial in China in Pa..
CI
2021Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to B..
CI
2021Jiangsu Nhwa Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter End..
CI
2021Jiangsu Nhwa Pharmaceutical Co., Ltd Approves Profit Distribution Plan for 2020 At the ..
CI
2021Jiangsu Nhwa Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended D..
CI
More news
Financials
Sales 2021 3 851 M 606 M 606 M
Net income 2021 871 M 137 M 137 M
Net cash 2021 1 611 M 254 M 254 M
P/E ratio 2021 18,6x
Yield 2021 0,75%
Capitalization 16 121 M 2 538 M 2 538 M
EV / Sales 2021 3,77x
EV / Sales 2022 3,13x
Nbr of Employees 4 451
Free-Float 44,5%
Chart JIANGSU NHWA PHARMACEUTICAL CO., LTD
Duration : Period :
Jiangsu Nhwa Pharmaceutical Co., LTD Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU NHWA PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 16,00 CNY
Average target price 17,28 CNY
Spread / Average Target 8,02%
EPS Revisions
Managers and Directors
Jia Quan Sun General Manager & Director
Ai Hao Gao Chief Financial Officer
Peng Sheng Sun Chairman
Feng Shou Wang Chairman-Supervisory Board
Xu Sheng Kong Independent Director